Price
Target price
-
-
-
-
-
?2.00
WKN: A3D3E9 / Symbol: RSLS / Name: Reshape Lifesciences / Stock / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Reshape Lifesciences Inc. Stock
The community is currently still undecided about Reshape Lifesciences Inc. with 1 Buy predictions and 0 Sell predictions.
On the other hand, the target price of 2 € is below the current price of 4.93 € for Reshape Lifesciences Inc., so the potential is actually -59.43%.
Our community identified positive and negative aspects for Reshape Lifesciences Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Reshape Lifesciences Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Reshape Lifesciences Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-01
At a first glance, a noteworthy aspect of Reshape Lifesciences' financial situation is the lack of available data in some important areas. For instance, the firm's market capitalization, P/E ratio, and EBITDA are all missing, making it challenging to form a precise evaluation of the company's valuation or profitability.
When analyzing Reshape Lifesciences' financials, several pros and cons emerge that warrant further consideration.
The foremost positive aspect highlighted from the data is the company's gross profit TTM that stands at $8,348,000. This number suggests that the company is able to generate profit from its core business operations, which is a vital sign of a healthy business.
